“The outlook revision reflects our view of Marshfield’s likely additional capital spending and possible debt over the next couple of years to execute on some key strategies, coupled with a financial operating profile that has improved in 2015 but has been somewhat uneven over the past few years,” said S&P credit analyst Suzie Desai.
S&P also affirmed the “A-” long-term rating on Marshfield Clinic’s series 2012B fixed rate bonds and the “A-” underlying rating on its series 2012B fixed rate revenue bonds.
More articles on healthcare finance:
6 hospitals with strong finances
S&P revises Verity Health System’s outlook to stable
S&P assigns ‘AA-‘ rating to Baylor Scott & White Health’s bonds
